A leading researcher whose work transformed the understanding of a devastating form of dementia has been awarded the 2026 Breakthrough Prize in Life Sciences. Dr. Rosa Rademakers, a neurogeneticist and medical advisor to the Association for Frontotemporal Degeneration, received the honor for her landmark discoveries linking specific genetic mutations to frontotemporal degeneration, or FTD.
Dr. Rademakers’ research identified that mutations in the progranulin gene and the C9orf72 gene are among the most common known causes of FTD, a progressive brain disorder that typically strikes people in their 50s and 60s. The C9orf72 mutation alone accounts for roughly 10 percent of all FTD cases and is also found in some forms of amyotrophic lateral sclerosis, or ALS. Her work helped establish that these genetic errors lead to toxic protein buildup in the brain, a mechanism now targeted by several experimental therapies.
For patients and families facing FTD, the discovery has been transformative. Prior to Dr. Rademakers’ findings, the genetic roots of the disease were largely unknown. Today, genetic testing can identify the cause in about one third of cases with a family history. This has opened the door to clinical trials aimed at slowing or stopping the disease. Several drug candidates designed to boost progranulin levels or silence the faulty C9orf72 gene are now in human testing, offering new hope where none existed before.
A Prize That Recognizes Rare Disease Research
The Breakthrough Prize, founded by Silicon Valley philanthropists, is one of the largest scientific awards in the world. It honors researchers whose work has produced major advances in understanding life sciences. Dr. Rademakers is the first scientist specifically recognized for FTD research, highlighting the growing importance of rare neurodegenerative diseases in the global research agenda.
Looking ahead, Dr. Rademakers continues to advise the FTD community and push for faster translation of genetic discoveries into treatments. With several promising clinical trials underway and a deeper molecular understanding of the disease, many experts believe the field is closer than ever to developing the first disease modifying therapy for FTD. For the thousands of families affected each year, that prospect is a reason for cautious optimism.